INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 43h ago
HOUSE PTR3h ago
SEC 13F3h ago
ROBINHOOD CHAIN3h ago
SEC FORM 4/Derivative conversionVerified data

Davidson Matt reported AZR

Director, President and CEO · Azora Therapeutics, Inc. (DE) · Azora Therapeutics, Inc. (DE) — Series A Preferred Stock

Side
C
Value
—
Shares
524.95
Price
—
Executed
Nov 2, 2026
Disclosed
Nov 4, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Nov 2 executedNov 4, 2026 disclosed

AZR · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
21/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Derivative conversion — administrative, little informational value

  • Relative size+13 / 25

No reported dollar value · 68.0% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · AZR

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    21
    DM
    Davidson MattDirector, President and CEO
    AZRAzora Therapeutics, Inc. (DE)
    Derivative conversion
    		C—
    525.0K sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    21
    DM
    Davidson MattDirector, President and CEO
    AZRAzora Therapeutics, Inc. (DE)
    Derivative conversion
    		C—
    101.3K sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    9
    DM
    Davidson MattDirector, President and CEO
    AZRAzora Therapeutics, Inc. (DE)
    Derivative conversion
    		C—
    101 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    21
    SJ
    Saiki JulieChief Strategy Officer
    AZRAzora Therapeutics, Inc. (DE)
    Derivative conversion
    		C—
    626.3K sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    21
    SJ
    Saiki JulieChief Strategy Officer
    AZRAzora Therapeutics, Inc. (DE)
    Derivative conversion
    		C—
    626 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001213900-26-115985
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Nov 2, 2026
    Published
    Nov 4, 2026
    Ingested by INSIDER
    Nov 4, 22:39 UTC
    Last re-read
    Nov 4, 23:10 UTC

    Extracted facts

    Filer
    Davidson Matt
    Role
    Director, President and CEO
    Transaction
    Derivative conversionAs filed: “C”
    Asset
    Azora Therapeutics, Inc. (DE) — Series A Preferred Stock
    Ticker
    AZR
    Shares
    524.95
    Price per share
    $0
    Execution date (reported)
    Nov 2, 2026
    Owned after transaction
    1,297 shares
    Days from execution to publication
    2

    What this establishes

    Davidson Matt filed this Form 4 reporting a derivative conversion of AZR on Nov 2, 2026. It became public on Nov 4, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director, President and CEO
    Davidson Mattcik:0001741937
    Issuer
    Azora Therapeutics, Inc. (DE)cik:0001513525

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.